The Economic Burden of Tenosynovial Giant Cell Tumors Among Employed Workforce in the United States.
J Occup Environ Med
; 63(4): e197-e202, 2021 04 01.
Article
em En
| MEDLINE
| ID: mdl-33560066
ABSTRACT
OBJECTIVE:
To assess the economic burden of tenosynovial giant cell tumor (TGCT) among US employed workforce.METHODS:
Patients with TGCT medical claims (Nâ=â1395) and matched controls (110) without TGCT claims (Nâ=â13,950) were identified from the OptumHealth Care Solutions, Inc. database (January 1, 1999 to March 31, 2017). Adjusted regression models were used to compare healthcare resource utilization, time lost from work, and associated costs between cohorts.RESULTS:
In patients with TGCT, the rates of inpatient admissions, emergency room visits, outpatient visits, and work loss days were 2.8, 1.5, 2.2, and 2.6 times those of matched controls, respectively (all Pâ<â0.001). Total annual all-cause healthcare costs and work loss-related costs were $9368 and $2708 higher for TGCT patients than for matched controls, respectively (all Pâ<â0.001).CONCLUSIONS:
TGCT was associated with a significant healthcare and work loss burden on US employers.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Efeitos Psicossociais da Doença
/
Tumor de Células Gigantes de Bainha Tendinosa
Tipo de estudo:
Health_economic_evaluation
/
Observational_studies
Limite:
Humans
País/Região como assunto:
America do norte
Idioma:
En
Revista:
J Occup Environ Med
Assunto da revista:
MEDICINA OCUPACIONAL
/
SAUDE AMBIENTAL
Ano de publicação:
2021
Tipo de documento:
Article